Glofitamab plus selinexor maintenance yields sustained CR in refractory DLBCL case
New treatment strategy shows promise for hard to treat lymphoma
This case report and literature review describes a 70-year-old man with primary refractory DLBCL harboring TP53 and CD58 mutations who achie…
A new treatment plan using glofitamab and selinexor helped a 70-year-old man with a very aggressive form of lymphoma achieve a lasting respo…
Sequential BTK inhibitor therapy maintains hematological and renal stability in Waldenström macroglobulinemia with renal dysfunction
New treatment approach shows promise for rare blood cancer patients
This case report and systematic review describes a patient with Waldenström macroglobulinemia and light-chain proximal tubulopathy treated w…
A new treatment plan for a rare blood cancer helped a patient maintain stable kidney function and a steady blood response.
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
Zanubrutinib shows high response rates in diffuse large B-cell lymphoma patients
A meta-analysis of 1,346 patients with diffuse large B-cell lymphoma shows zanubrutinib achieves high response rates and prolonged survival.…
Zanubrutinib helped 95 out of 100 previously untreated patients with diffuse large B-cell lymphoma respond to treatment in this analysis.
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs.
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Zanubrutinib-combined therapy in heavily treated non-GCB DLBCL: retrospective two-center cohort of 27 patients
New hope for tough lymphoma cases
A retrospective two-center cohort of 27 heavily treated patients with relapsed/refractory non-GCB DLBCL evaluated zanubrutinib-combined ther…
Combining zanubrutinib with other treatments helped 74% of patients with tough, hard-to-treat lymphoma respond after standard options failed…